CAD Impact On Clinical Decisions Warrants Guidance Document – Philips Rep
This article was originally published in The Gray Sheet
Executive Summary
The relationship between the performance of computer-aided detection (CAD) technologies and actual clinical outcomes merits clarification from FDA and CMS, according to Philips Nuclear Medicine Chief Medical Officer David Rollo